JOINDER AND MODIFICATION NO. 2 TO LOAN AND SECURITY agreementLoan and Security Agreement • July 5th, 2018 • Cancer Genetics, Inc • Services-medical laboratories
This Joinder and Modification No. 2 to Loan and Security Agreement (this “Second Modification”) is entered into as of June 30, 2018 (the “Second Modification Effective Date”) by and among (a) Partners for Growth IV, L.P., a Delaware limited partnership (“PFG”), and (b) each of (i) CANCER GENETICS, INC., a Delaware corporation (“Parent”), (ii) GENTRIS, LLC, a Delaware limited liability company (“Delaware Subsidiary” and together with Parent, individually and collectively, jointly and severally, the “Existing Borrower”), (iii) VIVOPHARM, LLC, a Delaware limited liability company (“Vivo”), and (iv) RDDT A VIVOPHARM COMPANY PTY LTD, a company incorporated under the laws of Australia (“Australian Borrower”, and together with Vivo, jointly and severally, individually and collectively, “New Borrower”) (Australian Borrower, together with Vivo and Existing Borrower, jointly and severally, individually and collectively, “Borrower”).
Cancer Genetics, inc. Omnibus Warrant AmendmentOmnibus Warrant Amendment • July 5th, 2018 • Cancer Genetics, Inc • Services-medical laboratories
This Omnibus Warrant Amendment (this “Amendment”) is entered into as of June 30, 2018 (the “Effective Date”), by and among Cancer Genetics, Inc., a Delaware corporation (the “Company”), as issuer, and each of Partners for Growth IV, L.P., a Delaware limited partnership (“PFG”), PFG Equity Investors, LLC, a Delaware limited liability company, and SVB Financial Group, a Delaware corporation (each a “Holder” and collectively, “Holders”). Capitalized terms used herein but not defined herein shall have the respective meanings ascribed to them in those certain Warrants issued by the Company to PFG and its designees named above dated as of March 22, 2017 (the “PFG Warrants”).
